What is the comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy?
Hare JM et al. compared allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy in a randomized trial. The results were published in JAMA in 2012 and showed that allogeneic bone marrow-derived mesenchymal stem cells had a better outcome in terms of ischemic cardiomyopathy compared to autologous bone marrow-derived mesenchymal stem cells.